BiotechTube

Ocrelizumab (US) + Ocrelizumab (EU) + ABP 692

Phase 3Recruiting
0 views this week 0 watching⚡ Active🧠Featured in Neuroscience Pipeline Watch
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing-remitting Multiple Sclerosis (RRMS)

Conditions

Relapsing-remitting Multiple Sclerosis (RRMS)

Trial Timeline

Jan 13, 2025 → Dec 17, 2027

NCT ID
NCT06700343

About Ocrelizumab (US) + Ocrelizumab (EU) + ABP 692

Ocrelizumab (US) + Ocrelizumab (EU) + ABP 692 is a phase 3 stage product being developed by Amgen for Relapsing-remitting Multiple Sclerosis (RRMS). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06700343. Target conditions include Relapsing-remitting Multiple Sclerosis (RRMS).

What happened to similar drugs?

7 of 20 similar drugs in Relapsing-remitting Multiple Sclerosis (RRMS) were approved

Approved (7) Terminated (6) Active (7)
🔄CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
❌DaclizumabAbbViePhase 3
❌BIIB019 (Daclizumab)AbbViePhase 3
🔄BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
🔄Rebif® + Avonex®MerckPhase 3
✅Rebif® + Rebif®MerckApproved
✅Interferon beta-1a (Rebif)MerckApproved

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06700343Phase 3Recruiting

Competing Products

20 competing products in Relapsing-remitting Multiple Sclerosis (RRMS)

See all competitors
ProductCompanyStageHype Score
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
47
LY2127399 + PlaceboEli LillyPhase 2
35
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
DaclizumabAbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
35
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
35
BIIB019 (Daclizumab)AbbViePhase 3
32
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
40
Rebif (Interferon beta-1a)MerckPre-clinical
26
Interferon beta-1aMerckPre-clinical
26
Rebif® + Avonex®MerckPhase 3
40
Rebif® + Rebif®MerckApproved
43
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
35
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
27
Interferon beta-1a (Rebif)MerckApproved
43
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
32
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
32
Interferon beta 1aMerckPre-clinical
26
Cladribine 10 mg oral tabletMerckApproved
39
Evobrutinib + Evobrutinib + Evobrutinib + Placebo + TecfideraMerckPhase 2
27